BlackRock, Inc. 13D and 13G filings for Cardiff Oncology, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-23 8:19 pm Purchase |
2025-03-31 | 13G | Cardiff Oncology, Inc. CRDF |
BlackRock Inc. BLK |
3,841,097 5.800% |
1,000,188 (+35.21%) |
Filing |
| 2025-02-05 5:28 pm Purchase |
2024-12-31 | 13G | Cardiff Oncology, Inc. CRDF |
BlackRock Inc. BLK |
2,840,909 4.300% |
105,328 (+3.85%) |
Filing |
| 2024-11-08 2:17 pm Unchanged |
2024-09-30 | 13G | Cardiff Oncology, Inc. CRDF |
BlackRock Inc. BLK |
2,735,581 5.900% |
0 (Unchanged) |
Filing |
| 2024-10-24 2:02 pm Purchase |
2024-09-30 | 13G | Cardiff Oncology, Inc. CRDF |
BlackRock Inc. BLK |
2,735,581 5.900% |
2,063,614 (+307.10%) |
Filing |
| 2022-07-08 4:56 pm Sale |
2022-06-30 | 13G | Cardiff Oncology, Inc. CRDF |
BlackRock Inc. BLK |
671,967 1.600% |
-1,860,281 (-73.46%) |
Filing |
| 2022-02-04 4:12 pm Purchase |
2021-12-31 | 13G | Cardiff Oncology, Inc. CRDF |
BlackRock Inc. BLK |
2,532,248 6.000% |
2,532,248 (New Position) |
Filing |